Comparing the current results to its competitors, Cognition Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, faster than the overall decrease of Cognition Therapeutics Inc 's competitors by 0 %, recorded in the same quarter.
Cognition Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes large and specialty biotechnology and pharmaceutical companies, academic research institutions, governmental agencies, and both public and private research organizations. Competitors vie in areas such as technology development and product candidate advancement. Many smaller biotechnology firms collaborate with larger established companies for research, development, commercialization, or to create treatments that may compete with the company's products. Competition is anticipated to increase due to the emergence of new therapies, technologies, and data. Numerous commercial and academic preclinical studies and clinical trials are ongoing in the central nervous system (CNS) field. Competitors often possess greater financial resources and expertise in research and development, manufacturing, regulatory approval, and marketing. Mergers and acquisitions within the biopharmaceutical sector may consolidate resources among fewer competitors. Smaller or early-stage companies may also present significant competition through collaborative efforts. Additionally, competitors compete in recruiting qualified personnel, establishing clinical trial sites, patient enrollment, and acquiring complementary technologies.
September 3, 2025
Cognition Therapeutics, Inc. is making notable strides in the field of neurodegenerative disorders with its lead investigational product, zervimesine (CT1812). As a clinical-stage company focused on drugs for conditions like Alzheimer’s disease and age-related macular degeneration, Cognition s recent developments signal promising pathways for intervention in multiple debilitating diseases. Enrollment Milestone in Alzheimer s TrialRecently, Cognition Therapeutics announced that its Phase 2 START Study, which investigates zervimesine in patients with mild cognitive impairment (MCI) and early Alzheimer’s disease, has reached a significant milestone 75% enrollment of its target of 540 individuals. This trial...
August 28, 2025
Cognition Therapeutics Inc., a biotechnology company specializing in therapies for neurodegenerative diseases, has recently announced a significant registered direct offering of common stock valued at $30 million. This move indicates confidence from investors but simultaneously sheds light on the entity s financial performance amidst a challenging competitive landscape. Financial SnapshotIn the second quarter of 2025, Cognition Therapeutics reported a year-on-year revenue decrease of 0%. This stagnancy is striking when compared to the broader market growth, with many of its competitors achieving an average revenue increase of 18.3% during the same period. The company also experienced a net loss despite witn...
August 22, 2024
Promising EEG Findings from Cognition Therapeutics Phase 2 SEQUEL Study for Alzheimer s Disease Treatment Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage biopharmaceutical company focused on developing drugs for neurodegenerative disorders, recently announced the publication of EEG findings from its Phase 2 SEQUEL study regarding its lead candidate, CT1812, for treating mild-to-moderate Alzheimer s disease. The study results were published in The Journal of Prevention of Alzheimer’s Disease, a peer-reviewed journal that adds credibility to the findings.The SEQUEL study was a single-site investigation involving 16 adults diagnosed with mild-to-moderate Alzheimer s disease. Participants in th...
July 29, 2024
Cognition Therapeutics, a biotechnology company dedicated to developing innovative treatments for neurodegenerative diseases, recently announced the results of its Phase 2 SHINE trial for CT1812, a drug formulated to address cognitive decline in patients with mild-to-moderate Alzheimer s disease. The results, reflecting a proof-of-concept stage, reveal promising advancements in cognitive outcomes among participants treated with CT1812 compared to those receiving a placebo. Key Findings from the SHINE TrialThe SHINE trial s results highlighted a remarkable ~40% mean improvement in cognitive measures for participants treated with CT1812. This statistic not only illustrates the drug s potential efficacy but als...
April 29, 2024
Cognition Therapeutics, a leading biopharmaceutical company, recently completed the enrollment process for its Phase 2 SHIMMER (Study to Highlight Imaging in Mild-to-Moderate Dementia with Lewy Bodies and - Top-line Results) study of their investigational drug CT1812. This groundbreaking study focuses on evaluating the potential efficacy of CT1812 in patients with mild-to-moderate dementia with Lewy bodies. With top-line results anticipated in the second half of 2024, this development holds significant promise for both Cognition Therapeutics and the patients affected by this debilitating condition.Outline of Facts:1. With enrollment successfully completed, Cognition Therapeutics has achieved a significant mi...
March 11, 2024
Cognition Therapeutics Plans Public Offering of Common Stock to Advance Neurodegenerative Disorder TreatmentsPURCHASE, N. Y., March 11, 2024 - Cognition Therapeutics, a clinical stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative disorders, has announced its intention to undertake an underwritten public offering of its common stock. The offering aims to generate funds to advance the company s pipeline of product candidates aimed at tackling these devastating conditions.Neurodegenerative disorders, such as Alzheimer s disease and Parkinson s disease, pose significant challenges for patients, caregivers, and the healthcare system. Cognition Therapeutics is at the fo...
March 6, 2024
Cognition Therapeutics Presents Groundbreaking Analyses Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer s Disease Studies at AD/PD 2024 ConferenceCognition Therapeutics, a clinical stage biotechnology company focused on developing novel treatments for neurodegenerative disorders, has recently presented significant findings at the AD/PD 2024 Alzheimer s and Parkinson s Diseases Conference in Lisbon, Portugal. The company showcased the results of proteomic and correlation analyses from two completed clinical studies, shedding light on the potential impact of their product candidate, CT1812, in treating Alzheimer s disease.The completed SEQUEL and SPARC studies, involving adults wit...
Publicly Traded Peers of Cognition Therapeutics inc
Acumen Pharmaceuticals Inc Share Performance
+37.72%
30 Days
Acumen Pharmaceuticals Inc
Profile
Acumen Pharmaceuticals Inc's business model focuses on developing innovative treatments and therapies for neurodegenerative diseases. They aim to address unmet medical needs through advanced research and cutting-edge technologies, with the goal of improving patients' lives and providing better healthcare solutions.
Cervomed Inc's business model focuses on developing and commercializing medical devices to address neurological disorders. They aim to provide innovative solutions to improve the quality of life for patients suffering from conditions like chronic pain and epilepsy. Through their research and development efforts, Cervomed Inc aims to bring technologically advanced products to market, catering to the needs of healthcare professionals and patients worldwide.
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Halozyme Therapeutics Inc is a biotechnology company that primarily focuses on developing and commercializing novel oncology therapies. Their business model involves leveraging their proprietary enzyme technology to improve the delivery and effectiveness of therapeutic drugs. By partnering with pharmaceutical companies, Halozyme aims to license their technology and collaborate on the development and commercialization of innovative therapies for various diseases.
Sources:
Cognition Therapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cognition Therapeutics inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
